Lexeo’s Approach To Gene Therapy For Common Conditions
CEO Expects First Commercial Launch As Early As 2026
Since becoming CEO of Lexeo a year before its launch, R. Nolan Townsend has steered the company from strength to strength, expanding its pipeline from three to eight novel therapeutics and ultimately developing therapeutics for a future where gene therapy can cut healthcare costs.
You may also be interested in...
Experts in drug development, clinical care and digital therapeutics discuss gaps in the treatment landscape for Alzheimer’s disease, as well as opportunities for prevention and innovation in care delivery.
The company, which has treatments in the clinic for CLN2 Batten disease and APOE4-associated Alzheimer’s disease, is developing AAV-mediated gene therapies designed for safer outcomes.
Executive changes at both Viatris and Teva in 2023 saw the companies shift their focus towards the innovator industry. Plus, trade groups saw some significant personnel shakeups, Alvotech expressed hope that new hires would help to resolve manufacturing approval issues, Biocon made changes to its management structure, and more.